HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 3087-3096

  Napolitano, Andrea ^a,b   Antoine, Daniel J ^c   Pellegrini, Laura ^a   Baumann, Francine ^a   Pagano, Ian ^a   Pastorino, Sandra ^a   Goparaju, Chandra M ^d   Prokrym, Kirill ^d   Canino, Claudia ^d   Pass, Harvey I ^d   Carbone, Michele ^a   Yang, Haining ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; FIBULIN; FIBULIN 3; HIGH MOBILITY GROUP B1 PROTEIN; HYPERACETYLATED HIGH MOBILITY GROUP B1 PROTEIN; MESOTHELIN; OSTEOPONTIN; UNCLASSIFIED DRUG; EFEMP1 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HMGB1 PROTEIN, HUMAN; SCLEROPROTEIN; SPP1 PROTEIN, HUMAN;

AREA UNDER THE CURVE; ARTICLE; BENIGN PLEURA EFFUSION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA EFFUSION; OCCUPATIONAL EXPOSURE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; ACETYLATION; ADULT; AGED; BLOOD; ENVIRONMENTAL EXPOSURE; FEMALE; LUNG TUMOR; MALE; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PLEURA TUMOR; YOUNG ADULT;

ACETYLATION; ADULT; AGED; ASBESTOS; BIOMARKERS; ENVIRONMENTAL EXPOSURE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GPI-LINKED PROTEINS; HMGB1 PROTEIN; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; OSTEOPONTIN; PLEURAL EFFUSION; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84966429389     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1130     Document Type: Article

References (49)

1. Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health 2013;19:1-10.
2. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227:44-58.
3. Baumann F, Ambrosi JP, Carbone M. Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol 2013;14:576-8.
4. IARC. Monograph: Asbestos (Chrysotile, Amosite, Crocidolite, Tremolite, Actinolite, and Anthophyllite). 2012 [cited 2015 May 13]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol100C/mono100C-11.pdf.
5. Hashim D, Boffetta P. Occupational and environmental exposures and cancers in developing countries. Annal Glob Health 2014;80:393-411.
6. Baumann F, Buck BJ, Metcalf RV, McLaurin BT, Merkler D, Carbone M. The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada. J Thorac Oncol 2015;10:731-7.
7. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite Exposure in North Dakota and in the Turkish Villages with Mesothelioma. Proc Natl Acad Sci USA 2011;108:13618-23.
8. Baumann F, Maurizot P, Mangeas M, Ambrosi JP, Douwes J, Robineau B. Pleural mesothelioma in New Caledonia: associations with environmental risk factors. Environ Health Perspect 2011;119:695-700.
9. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
10. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179.
11. Napolitano A, Pellegrini L, Dey A, Larson D, Tanji M, Flores EG, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2015 Jun 29. [Epub ahead of print].
12. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. Jpn J Thorac Cardiovasc Surg 2008;135:620-6, 6e1-3.
13. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317-24.
14. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541-9.
15. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
16. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012;367:1417-27.
17. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014;69:895-902.
18. Lin H, Shen YC, Long HY, Wang H, Luo ZY, Wei ZX, et al. Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a metaanalysis. Int J Clin Exp Med 2014;7:1289-96.
19. Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 2014;4:e004145.
20. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012;72:3290-301.
21. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A 2010;107:12611-6.
22. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
23. Huang SX, Partridge MA, Ghandhi SA, Davidson MM, Amundson SA, Hei TK. Mitochondria-derived reactive intermediate species mediate asbestos-induced genotoxicity and oxidative stress-responsive signaling pathways. Environ Health Perspect 2012;120:840-7.
24. Tanaka S, Choe N, Hemenway DR, Zhu S, Matalon S, Kagan E. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. Eur J Clin Invest 1998;102:445-54.
25. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22:5551-60.
26. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 2014;111:3068-73.
27. Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling. Am J Pathol 2013;183:1654-66.
28. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994;57:1395-401.
29. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995;59:835-44.
30. Lilis R, Ribak J, Suzuki Y, Penner L, Bernstein N, Selikoff IJ. Non-malignant chest x ray changes in patients with mesothelioma in a large cohort of asbestos insulation workers. Br J Ind Med 1987;44:402-6.
31. Ge X, Antoine DJ, Lu Y, Arriazu E, Leung TM, Klepper AL, et al. High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem 2014;289:22672-91.
32. Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 2012;56:1070-9.
33. Palmblad K, Schierbeck H, Sundberg E, Horne AC, Harris HE, Henter JI, et al. High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med 2015;20:538-47.
34. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
35. Kaya H, Demir M, Taylan M, Sezgi C, Tanrikulu AC, Yilmaz S, et al. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 2015;16:1403-7.
36. Agha MA, El-Habashy MM, El-Shazly RA. Role offibulin-3 in the diagnosis of malignant mesothelioma. Egyptian Journal of Chest Diseases and Tuberculosis 2014;63:99-105
37. Creaney J, Dick IM, Robinson BW. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr Opin Pulm Med 2015;21:352-6.
38. Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer 2015;113:936-9.
39. Blyth KG. Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax 2015;70:374.
40. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008;14:476-84.
41. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009;32:17-22.
42. Lantos J, Foldi V, Roth E, Weber G, Bogar L, Csontos C. Burn trauma induces early HMGB1 release in patients: its correlation with cytokines. Shock 2010;33:562-7.
43. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005;33:564-73.
44. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
45. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012;8:195-202.
46. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48:971-81.
47. Pullerits R, Urbonaviciute V, Voll RE, Forsblad-D'Elia H, Carlsten H. Serum levels of HMGB1 in postmenopausal patients with rheumatoid arthritis: associations with proinflammatory cytokines, acute-phase reactants, and clinical disease characteristics. J Rheumatol 2011;38:1523-5.
48. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, et al. Cholinergic anti-inflammatory path way activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007;13:210-5.
49. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, DeVuyst P, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012;141:477-84.